» Articles » PMID: 28182009

Hetero-oligomerization Between the TNF Receptor Superfamily Members CD40, Fas and TRAILR2 Modulate CD40 Signalling

Overview
Journal Cell Death Dis
Date 2017 Feb 10
PMID 28182009
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

TNF receptor superfamily members (TNFRSF) such as CD40, Fas and TRAIL receptor 2 (TRAILR2) participate to the adaptive immune response by eliciting survival, proliferation, differentiation and/or cell death signals. The balance between these signals determines the fate of the immune response. It was previously reported that these receptors are able to self-assemble in the absence of ligand through their extracellular regions. However, the role of this oligomerization is not well understood, and none of the proposed hypotheses take into account potential hetero-association of receptors. Using CD40 as bait in a flow cytometry Förster resonance energy transfer assay, TNFRSF members with known functions in B cells were probed for interactions. Both Fas and TRAILR2 associated with CD40. Immunoprecipitation experiments confirmed the interaction of CD40 with Fas at the endogenous levels in a BJAB B-cell lymphoma cell line deficient for TRAILR2. TRAILR2-expressing BJAB cells displayed a robust CD40-TRAILR2 interaction at the expense of the CD40-Fas interaction. The same results were obtained by proximity ligation assay, using TRAILR2-positive and -negative BJAB cells and primary human B cells. Expression of the extracellular domains of Fas or TRAILR2 with a glycolipid membrane anchor specifically reduced the intrinsic signalling pathway of CD40 in 293T cells. Conversely, BJAB cells lacking endogenous Fas or TRAILR2 showed an increased NF-κB response to CD40L. Finally, upregulation of TRAILR2 in primary human B cells correlated with reduced NF-κB activation and reduced proliferation in response to CD40L. Altogether, these data reveal that selective interactions between different TNFRSF members may modulate ligand-induced responses upstream signalling events.

Citing Articles

Design of pseudosymmetric protein hetero-oligomers.

Kibler R, Lee S, Kennedy M, Wicky B, Lai S, Kostelic M Nat Commun. 2024; 15(1):10684.

PMID: 39695145 PMC: 11655659. DOI: 10.1038/s41467-024-54913-8.


Editorial: Reviews and advances in inflammatory diseases and the tumor necrosis factor.

Smulski C Front Cell Dev Biol. 2024; 12:1399804.

PMID: 38655065 PMC: 11035870. DOI: 10.3389/fcell.2024.1399804.


Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.

Rakke Y, Buschow S, IJzermans J, Sprengers D Front Immunol. 2024; 15:1357333.

PMID: 38440738 PMC: 10910082. DOI: 10.3389/fimmu.2024.1357333.


Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.

Andreescu M Cureus. 2024; 16(1):e52050.

PMID: 38344573 PMC: 10857843. DOI: 10.7759/cureus.52050.


Editorial: TNFR Superfamily Oligomerization and Signaling.

Micheau O, Rizzi M, Smulski C Front Cell Dev Biol. 2021; 9:682472.

PMID: 33959618 PMC: 8093801. DOI: 10.3389/fcell.2021.682472.


References
1.
Strasser A, Jost P, Nagata S . The many roles of FAS receptor signaling in the immune system. Immunity. 2009; 30(2):180-92. PMC: 2956119. DOI: 10.1016/j.immuni.2009.01.001. View

2.
Hennino A, Berard M, Krammer P, Defrance T . FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J Exp Med. 2001; 193(4):447-58. PMC: 2195905. DOI: 10.1084/jem.193.4.447. View

3.
Tam S, Richmond D, Kaminker J, Modrusan Z, Martin-McNulty B, Cao T . Death receptors DR6 and TROY regulate brain vascular development. Dev Cell. 2012; 22(2):403-17. DOI: 10.1016/j.devcel.2011.11.018. View

4.
Zazzeroni F, Papa S, Algeciras-Schimnich A, Alvarez K, Melis T, Bubici C . Gadd45 beta mediates the protective effects of CD40 costimulation against Fas-induced apoptosis. Blood. 2003; 102(9):3270-9. DOI: 10.1182/blood-2003-03-0689. View

5.
Ursini-Siegel J, Zhang W, Altmeyer A, Hatada E, Do R, Yagita H . TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J Immunol. 2002; 169(10):5505-13. DOI: 10.4049/jimmunol.169.10.5505. View